Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03492671 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 2, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Sep 30, 2026 to Sep 2026v10
  2. Primary and study completion dates: Sep 30, 2024 to Sep 30, 2026v9
  3. 5 versions Re-verified since May 27, 2020, no change to tracked fieldsv4-v8
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2019 to Jul 17, 2019
    v3
  5. Start date: May 2018 to May 2019v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this phase 2 research study is to determine whether a combination of chemotherapy drugs plus radiation therapy, given before surgery in resectable pancreactic cancer, can help to increase the chances of surgeons achieving and R0 resection. The chemotherapy drugs used are gemcitabine and nab-paclitaxel. These drugs are both approved by the FDA for use in treating adults with pancreatic adenocarcinoma. The investigational portion of this study is providing the chemotherapy drugs and radiation therapy before surgery. Primary Endpoint, R) resection rate ≥70%. Secondary Endpoints, Disease free survival, Overall survival , Perioperative mortality and morbidity.
Trial Details
NCT Number NCT03492671
Lead Sponsor Loma Linda University
Conditions
(from sponsor)		 Pancreas Adenocarcinoma, Resectable Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov